CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TAKEDA PHARMACEUTICAL CO LTD

TAK
$60.25BLarge Cap

Next catalyst

Phase 2November 2026

TAK-360

Idiopathic Hypersomnia

Get an email about TAK's next catalysts

Track TAKEDA PHARMACEUTICAL CO (TAK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 16 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

17 upcoming, 1 past

Phase 2Next

TAK-360 Phase 2 Est. Readout

November 2026~TAK-36096

Estimated primary completion for TAK-360 trial (NCT06812078) in Idiopathic Hypersomnia. Topline data typically follows completion by weeks to months.

Source
Phase 2

Ixazomib Phase 2 Est. Readout

December 2026~Ixazomib79

Estimated primary completion for Ixazomib trial (NCT04009109) in Myeloma, Multiple. Topline data typically follows completion by weeks to months.

Source
Phase 2

FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Phase 2 Est. Readout

January 2027~FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)60

Estimated primary completion for FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) trial (NCT07011576) in Colon Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 3

Maribavir Phase 3 Est. Readout

January 2027~Maribavir80

Primary completion for Maribavir trial (NCT05319353) in Cytomegalovirus (CMV)

Source
Phase 2

Zasocitinib (Dose A) Phase 2 Est. Readout

February 2027~Zasocitinib (Dose A)90

Primary completion for Zasocitinib (Dose A) trial (NCT07244263) in Hidradenitis Suppurativa

Source
Phase 3

Teduglutide Phase 3 Est. Readout

February 2027~Teduglutide13

Primary completion for Teduglutide trial (NCT06973304) in Short Bowel Syndrome

Source
Phase 2

TAK-279 Phase 2 Est. Readout

February 2027~TAK-279268

Estimated primary completion for TAK-279 trial (NCT06233461) in Crohn's Disease. Topline data typically follows completion by weeks to months.

Source
Phase 2

C1 Esterase Inhibitor Injection Phase 2 Est. Readout

March 2027~C1 Esterase Inhibitor Injection128

Estimated primary completion for C1 Esterase Inhibitor Injection trial (NCT06359782) in Subarachnoid Hemorrhage, Aneurysmal. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaTOKYO49.6K employees

The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".

Website
Drug Pipeline

Teduglutide

Phase 3

Short Bowel Syndrome

IGSC

Phase 3

Primary Immunodeficiency Disease

Alogliptin and pioglitazone

Phase 3

Type 2 Diabetes Mellitus

Ramelteon

Phase 3

Sleep Initiation and Maintenance Disorders

TDV

Phase 3

Dengue Fever

Dexlansoprazole MR

Phase 3

Gastroesophageal Reflux Disease

Ixazomib

Phase 3

Multiple Myeloma

AMG 479

Phase 3

Adenocarcinoma of the Pancreas

SYR-472

Phase 3

Diabetes Mellitus

TAK-583

Phase 3

Neuralgia, Postherpetic

Darvadstrocel

Phase 3

Crohn's Disease

Omega-3-acid ethyl esters 90 (TAK-085)

Phase 3

Hypertriglyceridemia

TAK-536CCB

Phase 3

Grade I or II Essential Hypertension

Lansoprazole and naproxen and aspirin

Phase 3

Osteoarthritis

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

Phase 3

Colorectal Cancer

Pioglitazone and Metformin

Phase 3

Diabetes Mellitus

Idursulfase-IT

Phase 3

Hunter Syndrome

Lanadelumab

Phase 3

Angioedema

Azilsartan medoxomil and hydrochlorothiazide

Phase 3

Essential Hypertension

Olmesartan medoxomil and hydrochlorothiazide

Phase 3

Essential Hypertension

Alogliptin and insulin

Phase 3

Diabetes Mellitus

Rabeprazole sodium

Phase 3

Healthy Volunteers

Trelagliptin

Phase 3

Type 2 Diabetes Mellitus

Glimepiride

Phase 3

Diabetes Mellitus, Type 2

Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

Phase 3

Multiple Myeloma

Parathyroid hormone

Phase 3

Disruption or Dehiscence of Closure of Sternum or Sternotomy

Amoxicillin

Phase 3

H. Pylori Infection

Lubiprostone Capsule, Fasted

Phase 3

Healthy Volunteers

Epoetin alfa or Epoetin beta

Phase 3

Chronic Renal Failure

SHP615

Phase 3

Nervous System Diseases

Magnesium Pantoprazole

Phase 3

GERD

Olmesartan medoxomil-hydrochlorothiazide

Phase 3

Essential Hypertension

PEGylated Recombinant Factor VIII

Phase 3

Hemophilia A

Vortioxetine tablets

Phase 3

Major Depressive Disorder

ciclesonide (XRP1526)

Phase 3

Respiratory Tract Diseases

Leuprorelin

Phase 3

Prostatic Neoplasms

Resatorvid

Phase 3

Sepsis

Alogliptin and glyburide

Phase 3

Diabetes Mellitus

IGI

Phase 3

Multiple Myeloma

SYR-322-MET

Phase 3

Clinical Pharmacology

Vonicog Alfa

Phase 3

Von Willebrand Disease (VWD)

TAK-559

Phase 3

Diabetes Mellitus

Mezagitamab

Phase 3

Immune Thrombocytopenic Purpura (ITP)

Active Comparator

Phase 3

Psoriatic Arthritis

Alogliptin and voglibose

Phase 3

Type 2 Diabetes Mellitus

Dexlansoprazole MR QD

Phase 3

Gastroesophageal Reflux

Deucravacitinib

Phase 3

Plaque Psoriasis

Epoetin

Phase 3

Chronic Kidney Disease

von Willebrand factor (Recombinant)

Phase 3

Von Willebrand Disease

rVWF

Phase 3

Von Willebrand Disease (VWD)

Azilsartan medoxomil and olmesartan

Phase 3

Hypertension

Lu AA21004

Phase 3

Major Depressive Disorder

TAK-536TCH tablet

Phase 3

Essential Hypertension

YF-17D

Phase 3

Dengue

Ixazomib Citrate

Phase 3

Multiple Myeloma

Lapaquistat acetate and simvastatin

Phase 3

Hypercholesterolemia

Upadacitinib

Phase 3

Crohn's Disease

MOVIPREP

Phase 3

Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

Velaglucerase Alfa

Phase 3

Gaucher Disease

Lapaquistat acetate and rosuvastatin

Phase 3

Hypercholesterolemia

TAK-928

Phase 3

IO-resistant sqNSCLC

NE-58095 IR

Phase 3

Involutional Osteoporosis

Relugolix

Phase 3

Uterine Fibroids

REPLAGAL

Phase 3

Fabry Disease

TVP-1012

Phase 3

Parkinson's Disease

Actovegin

Phase 3

Peripheral Arterial Diseases

TachoSil®

Phase 3

Hemorrhage

Febuxostat

Phase 3

Gout

Epoetin Alfa

Phase 3

Myelodysplastic Syndrome

Apremilast

Phase 3

Plaque Psoriasis

TAK-330

Phase 3

Coagulation Disorder

Allopurinol

Phase 3

Gout

Voglibose

Phase 3

Type 2 Diabetes Mellitus

TAK-771

Phase 3

Primary Immunodeficiency Diseases (PID)

Surgicel® Original

Phase 3

Bleeding

TAP-144-SR(6M)

Phase 3

Prostate Cancer

Fasiglifam

Phase 3

Diabetes Mellitus, Type 2

Alogliptin Benzoate

Phase 3

Diabetes Mellitus, Type 2

Febuxostat IR

Phase 3

Gout

TAK-360

Phase 3

Idiopathic Hypersomnia

Metformin HCl

Phase 3

Diabetes Mellitus

TAK-667

Phase 3

Hereditary Angioedema

Leuprorelin SR

Phase 3

Prostatic Neoplasms, Locally Advanced

VONVENDI

Phase 3

Von Willebrand Disease (VWD)

Azilsartan medoxomil with or without add-on chlorthalidone

Phase 3

Hypertension

Eicosapentaenoic acid-ethyl (EPA-E)

Phase 3

Hypertriglyceridemia

Augmented autologous stem cell transplant (ASCT-aug)

Phase 3

Multiple Myeloma

ITD consolidation and ixazomib maintenance vs. No further therapy

Phase 3

Multiple Myeloma

Antihemophilic Factor (Recombinant)

Phase 3

Von Willebrand Disease

rozerem

Phase 3

Insomnia

Alogliptin and Metformin Fixed-Dose Combination (FDC)

Phase 3

Diabetes Mellitus

ITI

Phase 3

Hemophilia A

Febuxostat XR

Phase 3

Gout

Pioglitazone and Glimepiride

Phase 3

Diabetes Mellitus

trifluridine/tipiracil

Phase 3

Metastatic Oesogastric Adenocarcinoma

High Dose Colchicine (total dose)

Phase 3

Gout

Low-dose rtPA

Phase 3

Ischemic Stroke

FEIBA

Phase 3

Hemophilia A

MHOS/SHP615

Phase 3

Nervous System Diseases

NE-58095 DR

Phase 3

Involutional Osteoporosis

ADVATE

Phase 3

Von Willebrand Disease (VWD)

rFVIII

Phase 3

Von Willebrand Disease (VWD)

HYQVIA

Phase 3

Primary Immunodeficiency Diseases (PID)

Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications

Phase 3

Hypertension

Lapaquistat acetate and atorvastatin

Phase 3

Hypercholesterolemia

Glyburide

Phase 3

Diabetes Mellitus

Lapaquistat acetate and additional lipid-lowering therapy

Phase 3

Hypercholesterolemia

Azilsartan medoxomil with or without add-on hydrochlorothiazide

Phase 3

Hypertension

HCTZ

Phase 3

Essential Hypertension

TAK-536CCB tablet

Phase 3

Essential Hypertension

Colchicine

Phase 3

Atrial Fibrillation

Vedolizumab

Phase 3

Colitis, Ulcerative

TAK-861

Phase 3

Narcolepsy Type 1

Azilsartan medoxomil and chlorthalidone

Phase 3

Essential Hypertension

Glipizide

Phase 3

Diabetes Mellitus

Vortioxetine

Phase 3

Major Depressive Disorder

TAK-881

Phase 3

Primary Immunodeficiency Diseases (PID)

TAK-536

Phase 3

Hypertension

Alogliptin and metformin

Phase 3

Type 2 Diabetes Mellitus

Parathyroid Hormone (PTH)

Phase 3

Osteoporosis

Lapaquistat Acetate

Phase 3

Dyslipidemia

Alogliptin and glimepiride

Phase 3

Type 2 Diabetes Mellitus

Rapid-acting insulin secretagogue

Phase 3

Diabetes Mellitus

Brentuximab Vedotin

Phase 3

Lymphoma

Candesartan

Phase 3

Heart Failure

Glimepiride and Metformin

Phase 3

Diabetes Mellitus

Magnesium Esomeprazole

Phase 3

GERD

Elaprase

Phase 3

Hunter Syndrome

IGIV GAMUNEX®-C

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

rFVIIa

Phase 3

Hemophilia A

IGIV GAMMAGARD LIQUID/KIOVIG

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Venticute

Phase 3

Pneumonia

Alogliptin

Phase 3

Diabetes Mellitus, Type 2

Azilsartan medoxomil - chlorthalidone

Phase 3

Essential Hypertension

Azilsartan medoxomil

Phase 3

Essential Hypertension

Zasocitinib

Phase 3

Psoriatic Arthritis

TAK-019

Phase 3

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

TAK-438

Phase 3

Gastric Ulcers

Chlorthalidone

Phase 3

Hypertension

Adynovate

Phase 3

Hemophilia A

Bismuth-Containing Quadruple Therapy

Phase 3

Duodenal Ulcer

Azilsartan Medoxomil and amlodipine

Phase 3

Hypertension

Soticlestat

Phase 3

Dravet Syndrome (DS)

Lansoprazole

Phase 3

Esophagitis, Reflux

Vedolizumab IV

Phase 3

Moderately to Severely Active Ulcerative Colitis

Rosiglitazone

Phase 3

Diabetes Mellitus

Candesartan cilexetil

Phase 3

Essential Hypertension

Low Dose Colchicine (total dose)

Phase 3

Gout

TAK-536CCB + Hydrochlorothiazide

Phase 3

Grade I or II Essential Hypertension

TAK-279

Phase 3

Plaque Psoriasis

Lapaquistat acetate and ezetimibe

Phase 3

Hypercholesterolemia

9vHPV Vaccine

Phase 3

Dengue Fever

Vonoprazan

Phase 3

Gastroesophageal Reflux

Zopiclone

Phase 3

Balance

Elritercept

Phase 3

Myelodysplastic Syndromes

Dexlansoprazole

Phase 3

Gastroesophageal Reflux Disease

Ramipril

Phase 3

Hypertension

Valsartan

Phase 3

Hypertension

TAK-672

Phase 3

Acquired Hemophilia A

Vedolizumab SC

Phase 3

Ulcerative Colitis

Lubiprostone

Phase 3

Constipation

Gefarnate

Phase 3

Stomach Ulcer

TAK-755

Phase 3

Thrombotic Thrombocytopenic Purpura (TTP)

Intranasal Fentanyl Spray (INFS)

Phase 3

Break Through Pain

Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)

Phase 3

Dengue Fever

Metformin hydrochloride

Phase 3

Type 2 Diabetes Mellitus

Azilsartan

Phase 3

Hypertension

Lansoprazole microgranules suspension

Phase 3

Gastroesophageal Reflux Disease

Peginesatide

Phase 3

Anemia

Concomitant Antibiotic Therapy

Phase 3

Pouchitis

TAK-743

Phase 3

Hereditary Angioedema

Cyclobenzaprine HCl

Phase 3

Neck Pain

TAK-625

Phase 3

Alagille Syndrome (ALGS)

Fazirsiran Injection

Phase 3

Alpha1-Antitrypsin Deficiency

TAK-875

Phase 3

Diabetes Mellitus

TAK-003

Phase 3

Dengue Fever

TAK-816

Phase 3

Healthy Volunteers

Brigatinib

Phase 3

ALK-positive Advanced NSCLC

Cyproterone acetate

Phase 3

Adenocarcinoma, Prostate

Escitalopram

Phase 3

Treatment Outcome

Maribavir

Phase 3

Cytomegalovirus (CMV)

Tetravalent Dengue Vaccine (TDV)

Phase 3

Dengue Fever

TAK-816+ DPT-TAKEDA

Phase 3

Immunization

Lapaquistat acetate and lipid-lowering therapy

Phase 3

Type 2 Diabetes

Alectinib

Phase 3

ALK+ Advanced NSCLC

HAV Vaccine

Phase 3

Healthy Volunteers

B-MAD chemotherapy

Phase 2

Extranodal NK/T-cell Lymphoma

TAK-062

Phase 2

Celiac Disease

Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

Phase 2

Dengue Fever

Leuprorelin acetate

Phase 2

Endometriosis

TAK-853

Phase 2

Ovarian Cancer

FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

Phase 2

Colon Cancer

Pioglitazone and insulin

Phase 2

Diabetes Mellitus

Namilumab

Phase 2

Rheumatoid Arthritis

Ramelteon and doxepin

Phase 2

Sleep Initiation and Maintenance Disorders

Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Phase 2

Norovirus

TAK-788

Phase 2

Carcinoma, Non-Small-Cell Lung

Tak-228 & Tak-117

Phase 2

Triple Negative Breast Cancer

TIMP-GLIA

Phase 2

Celiac Disease

Subcutaneous injection of TAK-850

Phase 2

Influenza Infection

Chemotherapy Agents

Phase 2

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

TAK-128

Phase 2

Diabetic Neuropathies

Zasocitinib (Dose A)

Phase 2

Hidradenitis Suppurativa

Norwalk VLP vaccine

Phase 2

Acute Gastroenteritis

Pioglitazone and ramipril

Phase 2

Inflammation

TAK228

Phase 2

Ovarian Cancer

TAK-385

Phase 2

Uterine Fibroids

Immune Globulin Infusion (Human)

Phase 2

Hematologic Malignancies

NoV Vaccine

Phase 2

Healthy Volunteers

TAK-981

Phase 2

Advanced or Metastatic Solid Tumors

Rusfertide

Phase 2

Polycythemia Vera

GI.1/GII.4 (15/50)

Phase 2

Norovirus

TAK-101

Phase 2

Celiac Disease

Dazostinag

Phase 2

Solid Neoplasms

TAK-954

Phase 2

Postoperative Gastrointestinal Dysfunction

TAK-079

Phase 2

Primary Immune Thrombocytopenia

MCC-135

Phase 2

Congestive Heart Failure

Methotrexate (IT)

Phase 2

ALL, Childhood

TAK-063

Phase 2

Schizophrenia

Ondansetron

Phase 2

Nausea

TAK-662

Phase 2

Congenital Protein C Deficiency

TAK-919

Phase 2

Coronavirus Disease (COVID-19)

TAK-850

Phase 2

Influenza Infection

GDX012

Phase 2

Leukemia

Alisertib

Phase 2

Acute Myeloid Leukemia

Triple IT (Methotrexate, Hydrocortisone, Cytarabine)

Phase 2

ALL, Childhood

GI.1/GII.4 (50/50)

Phase 2

Norovirus

TAK-188

Phase 2

Advanced or Metastatic Solid Tumors

Levothyroxine sodium new formulation

Phase 2

Hypothyroidism

TD-8954

Phase 2

Enteral Feeding Intolerance

SHP655

Phase 2

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

GI.1/GII.4 (50/150)

Phase 2

Norovirus

TAK-783 and methotrexate

Phase 2

Arthritis, Rheumatoid

Norovirus Bivalent Vaccine

Phase 2

Prevention From Norovirus Infection

Panitumumab + TAS-102

Phase 2

Colorectal Cancer

TAK-935

Phase 2

Developmental and/or Epileptic Encephalopathies

Ramelteon and gabapentin

Phase 2

Sleep Initiation and Maintenance Disorders

Pevonedistat

Phase 2

Acute Myeloid Leukemia (AML)

TAK-226

Phase 2

Myelodysplastic Syndromes

TAK-505

Phase 2

Malignant Solid Tumors

Norwalk virus

Phase 2

Acute Gastroenteritis

C1 Esterase Inhibitor Injection

Phase 2

Subarachnoid Hemorrhage, Aneurysmal

Adcetris-Levact

Phase 2

Clinical Efficacy

TAK-071

Phase 2

Parkinson Disease

Leuprorelin (GF)

Phase 2

Uterine Fibroids

Olmesartan

Phase 2

Hypertension

AMG 706

Phase 2

Advanced Gastrointestinal Stromal Tumor

Fruquintinib Combined With Chemotherapy

Phase 2

Metastatic Colorectal Cancer (CRC)

BAX 888

Phase 2

Hemophilia A

TDV Liquid Formulation 2

Phase 2

Dengue Fever

Intramuscular injection of TAK-850

Phase 2

Influenza Infection

Ilaprazole

Phase 2

Esophagitis

TAK-715 and methotrexate

Phase 2

Arthritis, Rheumatoid

Niraparib

Phase 2

Ovarian Cancer

TDV Liquid Formulation 1

Phase 2

Dengue Fever

Lapaquistat acetate and fenofibrate

Phase 2

Hyperlipidemias

Melphalan

Phase 2

Multiple Myeloma

TAK-875 and Sitagliptin

Phase 2

Diabetes Mellitus, Type 2

Anti-CD19 CAR T Cells Preparation

Phase 2

Hematologic Malignancies

Pioglitazone and azilsartan

Phase 2

Diabetes Mellitus

HGT-1110

Phase 2

Metachromatic Leukodystrophy (MLD)

Asparaginase

Phase 2

ALL, Childhood

Luvadaxistat

Phase 2

Schizophrenia

Leuprorelin (GC)

Phase 2

Uterine Fibroids

Pioglitazone and atorvastatin

Phase 2

Cardiovascular Diseases

Cisplatin & Nab Paclitaxel

Phase 2

Triple Negative Breast Cancer

SHP611

Phase 2

Metachromatic Leukodystrophy (MLD)

Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

Phase 2

Dengue Fever

Prednisone (and methylprednisolone)

Phase 2

Immune Checkpoint Inhibitor-Related Colitis

TAK-341

Phase 2

Multiple System Atrophy

Norovirus Bivalent VLP Vaccine

Phase 2

Norovirus Prevention

Folic/folinic acid

Phase 2

Rheumatoid Arthritis

TAK-272

Phase 2

Type 2 Diabetes Mellitus and Microalbuminuria

TDV IDT Lyophilized

Phase 2

Dengue Fever

Hepatitis A Vaccine

Phase 2

Healthy Volunteers

NoV GI.1/GII.4 Bivalent VLP Vaccine

Phase 2

Norovirus

TAK-442

Phase 2

Acute Coronary Syndrome

TAK-007

Phase 2

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

GI.1/GII.4 (15/15)

Phase 2

Norovirus

vortioxetine (Lu AA21004)

Phase 2

Depressive Disorder, Major

TAK-411

Phase 2

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

TAK-951

Phase 2

Postoperative Nausea and Vomiting (PONV)

Ponatinib

Phase 2

Myeloid Leukemia, Chronic, Chronic Phase

NDI-034858 study drug

Phase 2

Moderate to Severe Plaque Psoriasis

NDI-034858

Phase 2

Psoriatic Arthritis

Frequently asked questions

What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→

CatalystAlert tracks 285 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TAK) pipeline across Phase 3, Phase 2. Its lead program is Ixazomib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→

TAKEDA PHARMACEUTICAL CO LTD's (TAK) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TAK biotech catalysts?→

Add TAK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply